TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>18 years old~* Patients diagnosed with Non-small cell lung cancer~* metastatic disease~* Afatinib treated in any line~* EGFR mutated~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive patients admitted in Cardiology Unit for coronary or peripheral angiography with lower fluid status defined on the basis bio-impedance analysis (Male with resistance/height ratio \> 315 Ohm/meter and Female \> 380 Ohm/meter).~Exclusion Criteria:~* contrast medium administration within the 10 days~* end stage renal failure requiring dialysis~* refused to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Standard saline infusion (Type: ACTIVE_COMPARATOR): All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
- Double saline infusion (Type: EXPERIMENTAL): All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Adenocarcinoma of the breast confirmed by biopsy~* Female Patients \>18 years of age~* Normal cardiac function~* Ability to perform activities of daily living with minimal assistance~* Chemotherapy naïve or have received prior chemotherapy \> 5 years ago~* Adequate bone marrow, liver and kidney function~* Be informed of the investigational nature of this study~* Sign an informed consent form~* Sentinel lymph node and/or axillary dissection prior to enrollment~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Life expectancy of \< than 6 months~* History of significant heart disease~* Prior chemotherapy or hormonal therapy~* Concurrent Trastuzumab therapy~* History of significant psychiatric disorders~* History of active uncontrolled infection~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* uncooperative children scored 1 or 2 on Frankle Scale.~* had no medical history of neurological or cognitive alterations.~* No facial deformities.~* ASA Classification I.~* requiring dental treatment under local anesthesia.~Exclusion Criteria:~* known allergy to midazolam or any other benzodiazepines.~* upper respiratory tract infection with nasal discharge.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- A (Midazolam) (Type: ACTIVE_COMPARATOR): 21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
- B (Lidocaine-Midazolam) (Type: EXPERIMENTAL): 21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
- C (Placebo) (Type: PLACEBO_COMPARATOR): 21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease~* Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study.~* Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP~* Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN~* Two or more oral ulcers over the 28 day period before screening, with or without current treatment~* Two or more oral ulcers at the time of randomization (Visit 2, Baseline)~Exclusion Criteria:~* Pregnant or breast feeding~* Any condition which places the subject at risk~* Systemic fungal infection~* History of TB infection within 3 years~* History of recurrent bacterial infection~* Mycobacterium TB as indicated by a positive PPD skin test~* History of incompletely treated Mycobacterium tuberculosis~* Clinically significant chest x-ray abnormality at screening.~* Clinically significant ECG abnormality at screening~* History of HIV infection~* History of congenital or acquired immunodeficiency~* Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening~* Antibodies to Hepatitis C at screening~* History of malignancy (except for treated basal-cell skin carcinomas \> 3 years prior to screening)~* Any active major organ involvement of Behçet Disease~* Use of concomitant immune modulating therapy or topical corticosteroids.~* Use of ocular corticosteroids~* Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A. Apremilast (Type: ACTIVE_COMPARATOR): None
- B. Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Autistic Disorder, Asperger's Disorder, or Pervasive Developmental Disorder not otherwise specified~* Weight \> 30 lbs~* IQ \>= 35 or mental age of at least 18 months~Exclusion Criteria:~* Psychotic Disorder~* History of intolerance or nonresponse to risperidone~* Pregnancy~* History of neuroleptic malignant syndrome

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- risperidone plus parent management training (Type: ACTIVE_COMPARATOR): None
- risperidone only (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~1. patient is over 18 years~2. ovarian carcinoma patients who are treated with moderately emetogenic chemotherapy~3. Karnofsky score \> 60~4. Life expectancy \> 4 months~Exclusion criteria~1. Any of following conditions (mentally incapacitated or emotional or psychiatric disorder, user of any illicit drugs, has an active infection, hypersensitivity to ramosetron or aprepitant)~2. Patients have received a nonapproved drug within last 4 weeks~3. abnormal laboratory values (AST \> 2.5 normal, ALT \> 2.5 normal, Bilirubin \> 1.5 normal, Creatinine \> 1.5 normal)~4. Antiemetic drugs within 48 hours of study~5. Benzodiazepine or opiate within 48 hours~6. CYP3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)~7. CYP3A4 inhibitors (clarithromycin, ketoconazole)~8. CYP3A4 inducers within 30 days (Barbiturates, rifampicin, carbamazepine)

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Aprepitant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Locally advanced or inflammatory disease~    * T4a-d, any N, M0 OR~   * Any T, N2 or N3, M0~   * Large operable T2 or T3 tumors~* No bilateral breast cancer~* Frozen tumor sample available~  * 1 incisional biopsy OR~ * 2 trucut biopsies from a 14G needle~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 70 and under~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.2 mg/dL~* SGOT less than 60 IU/L~Renal:~* Creatinine less than 1.35 mg/dL~Cardiovascular:~* LVEF normal by echocardiography or MUGA~Other:~* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No serious uncontrolled medical condition~* No uncontrolled psychiatric or addictive disorders~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- non taxane based chemotherapy (Type: ACTIVE_COMPARATOR): either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
- taxane based chemotherapy (Type: EXPERIMENTAL): Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thyroxine Replacement in Organ Donors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Brain death criteria established~2. Consent for organ donation received~Exclusion Criteria:~1. immediate (\< 4 Hrs) organ retrieval anticipated

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- po thyroxine (Type: ACTIVE_COMPARATOR): placebo is iv
- iv thyroxine (Type: ACTIVE_COMPARATOR): placebo is po

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Locally advanced disease or at high risk for relapse~* No clinically or radiologically suspected metastases~* Prior lymphadenectomy required~* Meets at least 1 of the following criteria for poor prognosis:~  * Gleason score greater than 7~ * T3 or T4 disease~ * Prostate-specific antigen greater than 20 ng/mL~ * N1 disease~PATIENT CHARACTERISTICS:~Age~* Under 80~Performance status~* ECOG 0-2~Life expectancy~* More than 10 years~Hematopoietic~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic~* AST and ALT no greater than 1.5 times upper limit of normal (ULN)~* Bilirubin no greater than ULN~Renal~* Creatinine less than 1.6 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Cardiovascular~* No uncontrolled or severe cardiovascular disease~* No prior thrombosis~Pulmonary~* No prior pulmonary embolus~Other~* No active infection~* No intolerance to aspirin~* No other prior malignancy except basal cell skin cancer~* No physical or psychological condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* No prior hormonal therapy~* No other concurrent hormonal therapy~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~Other~* No other concurrent anticancer therapy

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): None
- Without Chemotherapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control, defined as a central laboratory glycosylated hemoglobin (HbA1c) ≥8.0% and ≤ 10.5 % obtained at the screening visit~* Subjects should have been taking the same daily dose of metformin ≥ 1500 mg for at least 8 weeks prior to the enrollment visit and with no intake of other antihyperglycemic therapy for more than 14 days (consecutive or not) during 12 weeks prior to screening~* BMI \> 20.0 kg/m2 at the enrollment visit~* Males and Females, age ≥18 years old at time of screening visit~* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug~* Women must not be breastfeeding~Exclusion Criteria:~* Clinically diagnosed with Type I diabetes, known diagnosis of Maturity Onset Diabetes of Young (MODY), secondary diabetes mellitus or diabetes insipidus~* History of diabetic ketoacidosis~* Any of the following cardiovascular (CV)/Vascular Diseases within 3 months of the enrollment visit~  * Myocardial infarction~ * Cardiac surgery or revascularization (coronary artery bypass surgery Coronary Artery Bypass Graft \[(CABG)\]/percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty \[(PTCA)\])~ * Unstable angina~ * Unstable congestive heart failure (CHF)~ * Transient ischemic attack (TIA) or significant cerebrovascular disease~ * Unstable or previously undiagnosed arrhythmia~ * Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute congestive heart failure and/or known left ventricular ejection fraction of ≤ 40%~* Renal Disease~* Hepatic Diseases~* Hematological and Oncological Disease/Conditions~* Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women~* Abnormal Free T4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- A1:Saxagliptin / Placebo + Dapagliflozin / Placebo (Type: EXPERIMENTAL): Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
- A2: Sitagliptin / placebo (Type: EXPERIMENTAL): Sitagliptin 100 mg and matching placebo 0 mg (once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients in Ethiopia with a diagnosis of podoconiosis. That is those living above 1000 feet sea level with high rainfall, above 1,00mm annually with foot or lower leg oedema which had started in the feet, with sensation present in the feet and no hand involvement. The diagnosis was determined by the nurses at the outreach clinics.~* Patients who were able to understand instructions and give informed consent as determined by the nurses at the outreach clinics.~* Patients over 18 years of age.~Exclusion Criteria:~* Patients not diagnosed with podoconiosis as determined by nurses at the outreach clinics.~* Patients who were unable to understand instructions or give informed consent as determined by nurses at the outreach clinics.~* Patients under 18 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Current skin care regimen (Type: ACTIVE_COMPARATOR): Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
- Current skin regimen plus 2% glycerine (Type: EXPERIMENTAL): Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete